Archives: Agenda

Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will be led by a table moderator and will focus on a different challenge within oncology and orphan drug clinical trials. Roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

1. Discussing the increased role of China R&D in developing new products
   Hosted by Sezcan Ozturk, Vice President, Head of Europe, Luzsana Biotechnology
2. AI in clinical operations
   Hosted by Pietro Belligoli, Researcher, Former Roche
3. Running trials in low-cost countries
   Hosted by Martin Neumayer, Head Development Program Support and CRO-Vendor Management, Sandoz
4. What is the best framework of strategies, processes and pathways for pharma and patient organisations to create positive, lasting partnerships?
   Hosted by Dr. Anupoma Haque, EUPATI Fellow, Patient-Centric Public & Digital Health Expert, HTA and Policy Professional, Inclusion & Equity Trainer

• Data-driven Selection to Choose a Region for Your Trial Expansion
• Risk Response Strategies and a Mitigation Framework
• Clear Communication and a Culture of Accountability Among Partners
• Case Studies on Canada as a Trial Expansion Region

• How to ensure your study is prioritised in a competitive industry
• Aligning CRO, site and sponsor priorities so everyone is supported in working towards the same goal
• Successfully partnering a CRO team with your internal departments to allow for effective communication across all stages of the trial
• CRO monitoring and oversight: How to make processes efficient and effective

Moderator: Asiyah Nawab, Senior Healthcare Analyst (Immunology Team), GlobalData

Early-phase oncology development is evolving rapidly, with a growing need for smarter trial designs, faster regulatory pathways, and deeper collaboration with sites. This session explores how AI-driven protocol design, streamlined fast-track approvals, and strategic site partnerships can transform study execution from design to delivery. Through practical insights and real-world examples, we will discuss how technology and collaboration with regulators and sites can help bring therapies to patients faster.

• Fast, Furious, or Never-Ending: Entertaining Case Studies on Accelerating and Unexpectedly Inflating Phase Ib/II Trial Timelines and Budgets. A Site Team Perspective.